期刊
RHEUMATOLOGY INTERNATIONAL
卷 -, 期 -, 页码 -出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00296-022-05213-1
关键词
Ankylosing spondylitis; Interleukin-17A; Obesity; Tumor necrosis factor inhibitors
类别
This study evaluated the retention rate of secukinumab in r-AxSpA patients and identified predictive factors. The global retention rate of secukinumab was 55% at 12 months. Obesity was found to be associated with a lower risk of secukinumab discontinuation, while multiple TNFi usage increased the risk. This real-life analysis suggests that obesity may not be an adverse risk factor for secukinumab drug retention in r-AxSpA.
The drug retention rate has been an important indicator for evaluating the treatment tolerance. Unfortunately, our knowledge of the secukinumab retention rate in radiographic axial spondyloarthritis (r-AxSpA) is limited. The objective of this study was to assess the retention rate of secukinumab and evaluate predictive factors of drug survival based on data from a real-life cohort. We retrospectively assessed 147 r-AxSpA patients between May 2018 and January 2020 from the HUR-BIO database. Secukinumab retention rates were analyzed using the Kaplan-Meier method and Cox proportional hazard model was used for predictors factors. The global retention rate of secukinumab was 55% at 12 months. r-AxSpA patients with obesity had a lower frequency of secukinumab discontinuation (29% vs. 50%, p = 0.013) in comparison r-AxSpA patients without obesity. In multivariate analysis, multiple TNFi usage had a higher risk of secukinumab discontinuation [HR 1.99 (1.09-3.62), p = 0.024]; on the other hand, obesity had a lower risk [HR 0.45 (0.27-0.90), p = 0.008]. Except for not using multiple TNFi, this real-life analysis showed for the first time that obesity is not an adverse risk factor for secukinumab drug retention in r-AxSpA. Secukinumab, which is an interleukin-17A inhibitor, could act via a different pathway than tumor necrosis factor inhibitors (TNFi). The identification of predictive factors such as obesity that may affect the individual drug selection may provide more appropriate biologic treatment strategies for r-AxSpA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据